Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M854Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-4.5EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)22.0Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book5.910-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M8,750,002ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with FBT

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

FBT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


FBT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Element, MartynDirector 2016-08-08Buy10,000$0.1564940view
Finch, S. WayneDirector, Senior Officer 2016-08-08Sell200$12.1706.28view
Finch, S. WayneDirector, Senior Officer 2016-08-08Sell1,800$12.1706.28view
Finch, S. WayneDirector, Senior Officer 2016-08-08Sell2,000$12.11705.62view
Ghuldu, RishiSenior Officer 2016-08-08Sell149$23.45316.03view
Louis, PeterSenior Officer 2016-08-08Sell5,000$87.8611.04view
Omni-Lite Industries Canada InIssuer 2016-08-08Buy5,000$1.75638.82view
Omni-Lite Industries Canada InIssuer 2016-08-08Buy4,700$1.655812.73view
Kovacevic, John GianniDirector, Senior Officer 2016-08-08Buy200,000$0.08121850view
Espaillat Lamarche, Julio ErneSenior Officer 2016-08-08Sell190,000$0.616160view

Quarterly/Annual Reports about FBT:

    News about FBT:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    What Should We Expect from BioMarin’s Kuvan in 2016? Aug 26 2016
    What’s BioMarin’s Expected Revenue Growth in 2016 and 2017? Aug 25 2016
    Did Hillary Clinton's Tweet Cause the Sell-Off in Mylan (MYL) Stock? Aug 24 2016
    How Xtandi Fueled Big Pharmaceutical Interest in Medivation Aug 24 2016
    Another Endorsement for Biotech ETFs Aug 16 2016
    Biotech Breakout: Take 3 Aug 04 2016
    Big Biotech Buyout Banter Buoys IBB Aug 02 2016
    How Much Will BioMarin’s Kuvan Fetch in 2Q16? Aug 02 2016
    What’s behind the Recent Fall in Alexion’s Valuation Multiple? Jul 25 2016
    How Much Will Orkambi Fetch for Vertex Pharmaceuticals in 2Q16? Jul 22 2016
    How Can Alexion Stay ahead of the Competition with Soliris? Jul 22 2016
    ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016 Jul 14 2016
    Biotech ETFs: Will the Once Hot Group Rebound? Jul 13 2016
    Inside Alnylam Pharmaceuticals’s Analyst Recommendations in 2016 Jul 08 2016
    Regeneron in 2Q16: How Much Revenue Growth Could It Have? Jul 08 2016
    Inside BioMarin’s Big Plans for 3Q16 Jul 06 2016
    Biotechs Building Base?...Or Bursting Bubble? Jun 30 2016
    BioMarin’s Guidance for 2016: The Inside Story Jun 29 2016
    As Cost Panel Gets Delayed, Buy These 3 Biotech ETFs Jun 23 2016
    Expect More Election Year Volatility For Biotech ETFs Jun 21 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)